Shernan Holtan, Chief of Blood and Marrow Transplantation and Professor of Medicine at Roswell Park Comprehensive Cancer Center, shared a post on LinkedIn about an article she co-authored with colleagues:
“New report from Megan M. Herr and team at Roswell Park Comprehensive Cancer Center!
In a 2022–2024 case series of people with Multiple Myeloma treated with ciltacabtagene autoleucel (Carvykti), movement and neurocognitive treatment-emergent events occurred in 19% (4/21) and were associated with very poor one-year survival (25% vs 81%).
A simple pre-infusion physical therapy test identified who developed these events in this cohort, suggesting a practical way to flag high-risk patients earlier for closer monitoring and prevention strategies.”
Title: Pretreatment physical function as a risk factor for movement and neurocognitive treatment-emergent events (MNTs) in multiple myeloma (MM) patients treated with cilta-cel
Authors: Megan M. Herr, Nisha M. Nair, Theresa Hahn, Chelsea Peterson, Jens Hillengass, Hillary Jacobson, Grant Schofield, Philip L. McCarthy, Ehsan Malek, Renee McKenzi, Hamza Hassan, Joseph D. Tario, Maureen Ross, Marco L. Davila, Brian C. Betts, Shernan Holtan
More posts featuring Shernan Holtan on OncoDaily.
